Biotechnology

Kura Oncology

Kura Oncology released FY2026 Q1 earnings on May 12 After-Market EST, actual revenue USD 18.27 M (forecast USD 25.92 M), actual EPS USD -0.83 (forecast USD -0.8243)

Kura Oncology to Release FY2026 Q1 Earnings on May 12 After-Market EST, Forecast Revenue USD 25.92 M, EPS USD -0.8243

Kura Oncology released FY2025 earnings on March 5 Pre-Market (EST), actual revenue USD 67.48 M (forecast USD 85.38 M), actual EPS USD -3.1783 (forecast USD -3.001)

Kura Oncology released FY2025 Q4 earnings on March 5 Pre-Market EST, actual revenue USD 17.34 M (forecast USD 35.45 M), actual EPS USD -0.9199 (forecast USD -0.7412)

Kura Oncology to Release FY2025 Q4 Earnings on March 5, 2026 Pre-Market EST, Forecast Revenue USD 35.45M, EPS USD -0.7412

Kura Oncology Advances ziftomenib Clinical Strategy and Expands Solid Tumor Pipeline

Kura Oncology's CSO Francis Burrows Reports Disposition of Common Stock

Kura Oncology Director Faheem Hasnain Disposes of Common Stock

Kura Oncology and Kyowa Kirin Announce Positive Results of KOMET-007 Trial of KOMZIFTI in Treatment of Acute Myeloid Leukemia

Kura Oncology to Host Virtual Meeting to Discuss Acute Myeloid Leukemia Drug Treatment Data

Kura Oncology Completes First Commercial Sale in the US Post FDA Approval

Kura Oncology Receives FDA Approval for KOMZIFTI™

Kura Oncology Inc Official Submits Form 144 to Sell Restricted Stock

Kura Oncology Officer Submits Form 144 to Sell 8,887 Shares

Barclays analyst maintains buy rating on Kura Oncology

FDA Approves KOMZIFTI for NPM1 Mutated Acute Myeloid Leukemia

Kura Oncology's drug approved by FDA for rare blood cancer treatment

Zacks Research Upgrades Kura Oncology to 'Hold'

Analyst Zelin Covers Healthcare Industry and Focuses on Specific Stocks

Charles Zhu Reiterates Buy Rating on Kura Oncology

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Micware

BiomX

Vida Global

MetaVia

MicroAlgo

Tradr 2X Long XNDU Daily ETF

KURA

LABU

SBIO

IBBQ

ARKG

Wall Street Zen upgraded Kura Oncology (NASDAQ:KURA) from a 'strong sell' to a 'hold' rating. Other analysts have also adjusted their ratings, with Wedbush and Mizuho lowering price targets. Kura's consensus rating is 'Moderate Buy' with a target price of $26.38. The company reported a quarterly EPS of ($0.83), beating estimates, but had a negative net margin of 411.19%. Kura's stock opened at $9.22, with a market cap of $818.46 million.

Market Beat

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

iShares Global Healthcare

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Mizuho Financial

Mizuho Financial Group, Inc.

UBS Group AG

SEI Investments

Barclays

Kura Oncology (NASDAQ:KURA) Rating Increased to Hold at Wall Street Zen

Earnings Watch

Kura Oncology | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 18.27 M

Kura Oncology | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 18.27 M

KOPN

Kopin Corporation Reports First Quarter 2026 Financial Results | KOPN Stock News

StockTitan

Kopin

Kopin Corporation Reports First Quarter 2026 Financial Results | KOPN Stock News

4151

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress | KURA Stock News

Kyowa Kirin Co., Ltd.

VG Health

Health Care Select Sector SPDR

iShares US Pharma

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress  | KURA Stock News

On May 5, 2026, Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focusing on precision medicines for cancer treatment, revealed that it is set to disclose its financial results for the first quarter of 2026 post the closure of U.S. financial markets on May 12, 2026. The management of Kura will conduct a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day to delve into the financial outcomes and present a corporate update.

Unusual Whales

Kura Oncology to Report First Quarter 2026 Financial Results

Kyowa Kirin and Kura Oncology have initiated a Phase II trial of ziftomenib for adult patients with relapsed or refractory NPM1-mutated acute myeloid leukaemia (AML) in Japan. The trial aims to assess the efficacy and safety of ziftomenib, with a primary endpoint of composite complete remission rate. Following the trial, Kyowa Kirin plans to seek regulatory approval in Japan. Ziftomenib, approved by the FDA in November 2025, offers a new treatment option for patients with limited alternatives.

WorldPharmaceuticals

Kyowa Kirin and Kura initiate Phase II trial of ziftomenib for AML

LifeSci Capital analyst Charles Zhu has maintained a Buy rating on Kura Oncology, setting a price target of $28.00. His recommendation is based on promising clinical data from the FIT-001 study, where the combination of darlifarnib and cabozantinib showed response rates exceeding expectations. Zhu notes the manageable safety profile and early signs of treatment durability, supporting a favorable risk-reward scenario in the post-IO renal cell carcinoma setting.

- Analyst Charles Zhu from LifeSci Capital maintains a "Buy" rating on Kura Oncology with a target price of $28.00, based on new clinical data and its strategic positioning in renal cell carcinoma.  
- Zhu highlights promising results from the FIT-001 study, where the combination of darlifarnib and cabozantinib achieved response rates exceeding expectations for previously treated patients.  
- He concludes that the manageable safety profile of cabozantinib and positive early tolerability signals support a favorable risk-reward outlook, justifying his continued recommendation to buy KURA.

Tip Ranks

Kura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating

Health care stocks rose on Friday, with the NYSE Health Care Index up 1.7%. Merck shares increased by 2.3% following European Commission approval of Enflonsia for respiratory diseases in infants. Kura Oncology saw a nearly 7% jump after positive trial data for darlifarnib. Psyence Biomedical shares surged 66% amid reports of a US executive order evaluating ibogaine's therapeutic potential for PTSD and addiction. The company has invested in ibogaine manufacturing through PsyLabs.

Kura Oncology(KURA.US)

Kura Oncology (NASDAQ:KURA) Rating Increased to Hold at Wall Street Zen

Kura Oncology | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 18.27 M

Kura Oncology | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 18.27 M

Kopin Corporation Reports First Quarter 2026 Financial Results | KOPN Stock News

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress | KURA Stock News

Kura Oncology to Report First Quarter 2026 Financial Results

Kyowa Kirin and Kura initiate Phase II trial of ziftomenib for AML

Kura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating

Sector Update: Health Care Stocks Higher Friday Afternoon